NuGEN Continues with Investment Across Worldwide Territories

San Carlos, California , Jan 31, 2017

NuGEN Technologies, Inc. announced the appointment of new distribution agreements, and Director of Sales - Worldwide Territories.

“With the addition of our new partners, NuGEN has dramatically improved access to its innovative technology” said Nitin Sood. “We are also pleased that these relationships and our customer support will be managed directly by Michael Abdo, Director of Sales who is based in the region”

Michael Abdo, Ph.D. joins NuGEN from PerkinElmer, where he served as Business Development Leader - Asia Pacific for several years, spanning a portfolio of products in automation and NGS sample prep. Prior to his current role, Dr. Abdo was engaged in the clinical genomics setting (PathWest), having undertaken postdoctoral studies at CSIRO and the Department of Agriculture, Western Australia. He holds a Doctorate in Molecular Biology and Master's degree in Biotechnology & Business.

Dr. Abdo commented "NuGEN’s simple, clean and cost-effective workflows are ideally suited to the region, as is the emphasis on improving human health, and food productivity and security. It’s certainly an exciting time to be a part of the NuGEN team and represent the brand outside of its core markets in the United States and Europe."

NuGEN Technologies has confirmed key distribution agreements with MDxK, Inc., ASONE, Genomax and Apsalagen in South Korea, Japan, Singapore and Thailand. More information on distributors and partnership opportunities can be found at www.nugen.com/company/distributors.

About NuGEN Technologies, Inc.

Based in San Carlos, CA, NuGEN Technologies, Inc. provides innovative products used to prepare biologic samples for targeted genomic analysis. NuGEN products are used in more than 1000 leading life science institutes and in diagnostic and pharmaceutical companies in 40 countries. It has a long history of launching products with market leading specs, including the recent launch of Ovation SoLo RNA Seq System that enables targeted depletion of unwanted transcripts and library construction from single cells, and Ovation Fusion Panel Target Enrichment System that enable detection of gene fusions across 502 genes that are implicated in cancer. To learn more about NuGEN visit www.nugen.com.

Media contact

Priya Balachandran, NuGEN Technologies, Inc., media@nugen.com